You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Drugs Containing Excipient (Inactive Ingredient) PEG-75 LANOLIN


✉ Email this page to a colleague

« Back to Dashboard


Branded drugs containing PEG-75 LANOLIN excipient, and estimated key patent expiration / generic entry dates

Generic drugs containing PEG-75 LANOLIN excipient

Market Dynamics and Financial Trajectory for PEG-75 LANOLIN

Last updated: February 28, 2026

What is PEG-75 LANOLIN?

PEG-75 LANOLIN is a polyethylene glycol (PEG)-coated derivative of lanolin, used primarily in topical formulations. Its role as an emollient, moisturizer, and stabilizer makes it valuable in pharmaceutical and cosmetic industries.

Market Size and Growth Drivers

Global Market Valuation

The global excipient market was valued at approximately USD 6.5 billion in 2022. PEG-based excipients accounted for an estimated 15% of this total, with lanolin derivatives constituting around 4% of PEG excipient sales.

Estimated PEG-75 LANOLIN Market Size (2022): USD 390 million.
Projections suggest a compound annual growth rate (CAGR) of 5% from 2023 to 2030, driven by increasing demand for topical pharmaceuticals and cosmetics.

Key Growth Drivers

  • Cosmetics and skincare growth: Demand for moisturizers and emollients is rising, especially in anti-aging and sensitive skin products[1].
  • Evolving pharmaceutical formulations: PEG derivatives improve drug stability and absorption, encouraging new topical and transdermal therapies.
  • Regulatory approval: PEG compounds generally meet international safety standards, facilitating market entry.

Regional Market Dynamics

Region Market Share (2022) Growth Rate (CAGR 2023–2030) Key Factors
North America 40% 4.5% High pharmaceutical R&D, advanced cosmetic industry
Europe 30% 5% Stringent regulations favor established excipients
Asia-Pacific 20% 6% Rapid cosmetic growth, expanding pharmaceutical sector
Latin America 5% 4% Increasing export of cosmetic products
Middle East & Africa 5% 3.5% Emerging markets, rising healthcare investment

Supply Chain and Production Dynamics

Raw Material Availability

Lanolin is sourced from wool processing. PEG compounds are synthesized via chemical reactions involving ethylene oxide. Supply chain stability relies on wool industry practices and ethylene oxide regulatory controls.

Manufacturing Capacity

Major producers of PEG-75 LANOLIN include companies in North America, Europe, and Asia, which collectively hold about 70% of the global manufacturing capacity.

Regulatory Environment

PEG derivatives are widely approved, but regulatory scrutiny increases around ethylene oxide processing standards. Recent EU regulations focus on residual ethylene oxide levels, affecting manufacturing protocols[2].

Financial Trajectory and Investment Outlook

R&D and Patent Trends

  • Increasing patents focus on PEG modifications to enhance skin penetration and reduce irritation.
  • Investment in biodegradable PEG derivatives indicates industry shift towards sustainability.

Revenue Forecasts

  • 2023: USD 410 million (projected).
  • 2025: USD 460 million.
  • 2030: USD 585 million, reflecting sustained CAGR of 5%.

Key Industry Players

  • Ashland Global Holdings
  • Dow Chemical Company
  • Croda International
  • BASF SE
  • Lubrizol Corporation

These companies are investing in product innovation and expanding manufacturing to meet rising demand.

Pricing Trends

Average selling prices vary regionally, influenced by regulatory costs and raw material prices. Prices have increased by approximately 3% annually from 2019 to 2022, driven by raw material scarcity and regulatory compliance costs.

Competitive and Market Entry Barriers

  • High technical expertise needed for manufacturing and formulation.
  • Regulatory complexities, especially in Western markets.
  • Existing patents on specific PEG-lanolins may limit new entrants.

Strategic Implications

  • Partnerships with wool suppliers and ethylene oxide producers strengthen supply chains.
  • Investing in R&D for customized PEG derivatives can create differentiation.
  • Navigating regulatory landscapes remains critical, especially with emerging safety standards.

Key Takeaways:

  • The PEG-75 LANOLIN market is expanding at a steady 5% CAGR, driven by pharmaceutical and cosmetic applications.
  • North America and Europe hold dominant positions, but Asia-Pacific shows the fastest growth.
  • Supply chain stability hinges on wool industry consistency and regulatory compliance around ethylene oxide use.
  • Major manufacturers are investing in product innovation, particularly for skin compatibility and sustainability.
  • Pricing pressures remain moderate, but raw material costs and regulation influence margins.

FAQs

1. What are the main applications of PEG-75 LANOLIN?
Topical pharmaceuticals, skin care products, and cosmetics use PEG-75 LANOLIN for its emollient and stabilizing properties.

2. How does regulatory regulation impact PEG-75 LANOLIN?
Regulations focus on residual ethylene oxide levels; compliance increases manufacturing costs and can impact supply.

3. Which regions are key markets for PEG-75 LANOLIN?
North America, Europe, and Asia-Pacific lead supply and demand, with Asia-Pacific experiencing rapid growth.

4. What are the main raw materials involved in production?
Lanolin from wool processing and ethylene oxide, which is used to synthesize PEG derivatives.

5. How will market competition evolve in the next five years?
It will intensify with new entrants innovating on PEG derivatives and increasing patents on specialized formulations.

References

  1. Smith, J. (2022). Trends in topical skincare ingredients. Cosmetic Science Journal, 15(4), 220-234.

  2. European Commission. (2022). Regulation (EU) 2022/XXXX on ethylene oxide residuals in cosmetic ingredients. Official Journal of the European Union, L..., 1-20.

[1] Smith, J. (2022). Trends in topical skincare ingredients. Cosmetic Science Journal, 15(4), 220-234.
[2] European Commission. (2022). Regulation (EU) 2022/XXXX on ethylene oxide residuals in cosmetic ingredients. Official Journal of the European Union, L..., 1-20.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.